Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common stock, $0.0001 par value
-
Shares outstanding
-
78.4M
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
201K
-
Shares change
-
+160K
-
Total reported value, excl. options
-
$230K
-
Value change
-
+$181K
-
Number of buys
-
7
-
Number of sells
-
-2
-
Price
-
$1.15
Significant Holders of CITIUS ONCOLOGY, INC. - Common stock, $0.0001 par value (CTOR) as of Q4 2024
12 filings reported holding CTOR - CITIUS ONCOLOGY, INC. - Common stock, $0.0001 par value as of Q4 2024.
CITIUS ONCOLOGY, INC. - Common stock, $0.0001 par value (CTOR) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 201K shares
of 78.4M outstanding shares and own 0.26% of the company stock.
Largest 10 shareholders include HRT FINANCIAL LP (68.5K shares), UBS Group AG (24.8K shares), CITADEL ADVISORS LLC (22.7K shares), IFP Advisors, Inc (22.2K shares), XTX Topco Ltd (21.1K shares), GEODE CAPITAL MANAGEMENT, LLC (12.7K shares), Yakira Capital Management, Inc. (12K shares), RENAISSANCE TECHNOLOGIES LLC (11.2K shares), OSAIC HOLDINGS, INC. (5.48K shares), and BANK OF AMERICA CORP /DE/ (160 shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.